Please login to the form below
TB
This page shows the latest TB news and features for those working in and with pharma, biotech and healthcare.
Roche collaborates with Global Fund to strengthen critical diagnostics infrastructure
The partnership is focused on helping patients with HIV and TB in low- and middle-income countries. ... He added: “We are pleased to partner with Roche in expanding access to diagnostics tools for HIV and TB.
Latest news
-
GSK licenses its tuberculosis vaccine to Gates MRI
According to the World Health Organization (WHO), TB remains one of the top ten causes of death worldwide, with around 10 million new cases of the infection reported in 2018 and ... older people, who accounted for 89% of people who fell ill with TB in
-
GSK's pivotal TB vaccine could prevent millions of deaths
GlaxoSmithKline has announced that its IAVI-partnered experimental tuberculosis (TB) vaccine candidate significantly reduced the occurrence of pulmonary tuberculosis disease. ... the only available vaccine, BCG, not providing a proven and consistent
-
J&J pledges $500m investment into HIV and tuberculosis R&D
In the TB therapy area, J&J will work with partners to improve detection methods for undiagnosed cases of the disease, and broaden the access to its targeted TB medicine bedaquiline – ... It also plans to accelerate R&D efforts to aid in the discovery
-
Gates’ non-profit biotech for poverty diseases sets out its stall at BIO
out research studies in western Kenya and her father’s battle with TB. ... number of avoidable deaths each year - 1.7m in the case of TB and around half a million apiece from malaria and diarrhoea/enteric diseases.
-
J&J expands its TB research programme
Johnson and Johnson (J&J) has partnered with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to develop new treatments for tuberculosis (TB). ... Paul Stoffels, chief scientific officer at
More from news
Approximately 6 fully matching, plus 60 partially matching documents found.
Latest Intelligence
-
GSK forges ahead with its dynamic COPD and asthma portfolio
Developing clarity. “COPD has not had the benefit of a unified treatment approach similar to that deployed in, for example, cardiac or TB medicine.
-
Tackling antimicrobial resistance on multiple fronts
We already have effective mechanisms that fund access to vaccines, TB, HIV and malaria.
-
Biotech profile: Tom Evans, CEO, Vaccitech.
Also, the present situation is that some of the diseases with greatest global need for new efficacious treatments, such as HIV, TB, Malaria, have been difficult to address using classical approaches
-
The cultural construction of illness
For example, in the 21st century TB is seen exclusively as an appalling condition linked with poverty, whereas in the early 19th century, fashionable metropolitans tried to cultivate a pleasingly pale
-
Reactivating drug research programmes
One research-led breakthrough to hit the headlines involves the use of genome sequencing to isolate different strains of tuberculosis (TB), allowing the disease to be diagnosed more quickly.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Dan Carucci becomes global chief medical officer of McCann Health
In addition, as vice president of global health at the United Nations Foundation, Carucci has also served on the board of the Global Fund to Fight AIDS, TB and Malaria.
-
Doctors.net.uk appoints new business development manager
UK-based laboratories and clinicians in the diagnosis of latent TB infection and TB disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Food Allergy – Is avoidance the only option?
Published October 1, 2021. Accessed April 28, 2022. BP V, A V, TB C, et al.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- Sanofi halts recruitment for trials assessing MS treatment
- Eli Lilly to make bebtelovimab commercially available to US states from August
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- ONS records a continued fall in UK COVID-19 infections
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
